VX-509 (Decernotinib) is a potent and selective Janus Kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 353, Issue 2, 2015, Pages 405-414

  Mahajan, Sudipta ^a   Hogan, James K ^a   Shlyakhter, Dina ^a   Oh, Luke ^c   Salituro, Francesco G ^b   Farmer, Luc ^a   Hoock, Thomas C ^a  

^a VERTEX PHARMACEUTICALS   (United States)

^b Sage Therapeutics Inc   (United States)

^c MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECERNOTINIB; ETANERCEPT; JANUS KINASE 3; OXAZOLONE; PREDNISOLONE; 2-((2-(1H-PYRROLO(2,3-B)PYRIDIN-3-YL)PYRIMIDIN-4-YL)AMINO)-2-METHYL-N-(2,2,2-TRIFLUOROETHYL)BUTANAMIDE; FUSED HETEROCYCLIC RINGS; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; DISEASE MODEL; EDEMA; ENZYMOLOGY; IMMUNOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; EDEMA; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; HYPERSENSITIVITY, DELAYED; INFLAMMATION; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MALE; MICE; PROTEIN KINASE INHIBITORS; RATS; VALINE;

EID: 84929939919     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.221176     Document Type: Article

References (29)

1. Cacalano NA, Migone TS, Bazan F, Hanson EP, Chen M, Candotti F, O'Shea JJ, and Johnston JA (1999) Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J 18: 1549-1558.
2. Carmona L, Cross M, Williams B, Lassere M, and March L (2010) Rheumatoid arthritis. Best Pract Res Clin Rheumatol 24:733-745.
3. Catlett, IM, Luo X, Penney MS, Pray ME, Spencer-Green G, Botfield M, and Hoock T (2012) Biomarker Assessment of VX-509, an Investigational Selective Inhibitor, in Healthy Volunteers. European League Against Rheumatism (EULAR) Congress; 2012 Jun 6-9; Berlin, Germany. EULAR Poster 2012 (THU0141).
4. Chen G, Porter MD, Bristol JR, Fitzgibbon MJ, and Pazhanisamy S (2000) Kinetic mechanism of the p38-alpha MAP kinase: phosphoryl transfer to synthetic peptides. Biochemistry 39:2079-2087.
5. Darnell JE, Jr (1997) STATs and gene regulation. Science 277:1630-1635.
6. Darnell JE, Jr, Kerr IM, and Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
7. Davies SP, Reddy H, Caivano M, and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105.
8. Ghoreschi K, Laurence A, and O'Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273-287.
9. Grossman WJ, Verbsky JW, Yang L, Berg LJ, Fields LE, Chaplin DD, and Ratner L (1999) Dysregulated myelopoiesis in mice lacking Jak3. Blood 94:932-939.
10. Ihle JN and Kerr IM (1995) Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 11:69-74.
11. Johnston JA, Bacon CM, Riedy MC, and O'Shea JJ (1996) Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. J Leukoc Biol 60:441-452.
12. Karras JG, Wang Z, Huo L, Frank DA, and Rothstein TL (1997) Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement. J Immunol 159:4350-4355.
13. Kiu H and Nicholson SE (2012) Biology and significance of the JAK/STAT signalling pathways. Growth Factors 30:88-106.
14. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O'Shea JJ, et al. (1995) Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377:65-68.
15. McInnes IB and Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205-2219.
16. Menet CJ, Rompaey LV, and Geney R (2013) Advances in the discovery of selective JAK inhibitors. Prog Med Chem 52:153-223.
17. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, Hoffmeyer A, van Deursen J, Sangster MY, Bunting KD, et al. (1999) Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10:249-259.
18. Müller M, Briscoe J, Laxton C, Guschin D, Ziemiecki A, Silvennoinen O, Harpur AG, Barbieri G, Witthuhn BA, Schindler C, et al. (1993) The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 366:129-135.
19. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, and Pfeffer K (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93:397-409.
20. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, Doherty PC, Grosveld GC, and Ihle JN (1995) Defective lymphoid development in mice lacking Jak3. Science 270:800-802.
21. O'Shea JJ and Plenge R (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36:542-550.
22. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, et al. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93:385-395.
23. Park SY, Saijo K, Takahashi T, Osawa M, Arase H, Hirayama N, Miyake K, Nakauchi H, Shirasawa T, and Saito T (1995) Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3:771-782.
24. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, et al. (1998) Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93:373-383.
25. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, et al. (1995) Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270:797-800.
26. Stark GR and Darnell JE, Jr (2012) The JAK-STAT pathway at twenty. Immunity 36:503-514.
27. Stevenson CS, Marshall LA, and Morgan DW, editors (2006) In Vivo Models of Inflammation: Progress in Inflammation Research, Birkhäuser, Basel.
28. Taylor N, Uribe L, Smith S, Jahn T, Kohn DB, and Weinberg K (1996) Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the gamma-c gene. Blood 87:3103-3107.
29. Watanabe S, Itoh T, and Arai K (1997) Roles of JAK kinase in human GM-CSF receptor signals. Leukemia 11 (Suppl 3):76-78.